Literature DB >> 15515156

Surgeons' and nurses' use of e-mail communication with head and neck cancer patients.

Sarah H Kagan1, Sean P Clarke, Mary Beth Happ.   

Abstract

BACKGROUND: "Telephone tag" for questions about postoperative symptoms and other concerns often engenders dissatisfaction. E-mail use may improve communication between patients and clinicians. This study aimed to describe surgeons' and nurses' use of E-mail with patients and their caregivers after head and neck cancer surgery.
METHODS: We conducted a cross-sectional national survey of head and neck nurses and surgeons.
RESULTS: Ninety-six percent of surgeon and 87% of nurse respondents used E-mail, but only 40% and 25%, respectively, used it with patients. More than 50% of both clinician groups that used E-mail with patients have done so for 2 to 5 years and began this practice at the request of patients. Surgeons not using E-mail with patients were twice as likely as nurses to cite privacy and liability issues, as well as time management and miscommunication concerns.
CONCLUSIONS: Some clinicians use E-mail with patients, most often by patient request. Medicolegal and clinical ramifications require further study. 2004 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2005        PMID: 15515156     DOI: 10.1002/hed.20119

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  3 in total

1.  Patients with cancer and e-mail: implications for clinical communication.

Authors:  David Dilts; Sheila H Ridner; Alejandro Franco; Barbara Murphy
Journal:  Support Care Cancer       Date:  2008-12-03       Impact factor: 3.603

Review 2.  E-mail in patient-provider communication: a systematic review.

Authors:  Jiali Ye; George Rust; Yvonne Fry-Johnson; Harry Strothers
Journal:  Patient Educ Couns       Date:  2009-11-13

3.  Email communication in a developing country: different family physician and patient perspectives.

Authors:  Nisrine N Makarem; Jumana Antoun
Journal:  Libyan J Med       Date:  2016-11-16       Impact factor: 1.657

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.